The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis

The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis

Objective. To evaluate the association of -174G/C IL-6 polymorphism with failure in therapeutic response to methotrexate (MTX) or leflunomide (LEF). This prospective, observational cohort included 96 Mexican-Mestizo patients with moderate or severe rheumatoid arthritis (RA), initiating MTX or LEF, g...

Full description

Bibliographic Details
Main Authors: A. J. Ruiz-Padilla, J. I. Gamez-Nava, A. M. Saldaña-Cruz, J. D. Murillo-Vazquez, M. L. Vazquez-Villegas, S. A. Zavaleta-Muñiz, B. T. Martín-Márquez, J. M. Ponce-Guarneros, N. A. Rodriguez Jimenez, A. Flores-Chavez, F. Sandoval-Garcia, J. C. Vasquez-Jimenez, E. G. Cardona-Muñoz, S. E. Totsuka-Sutto, L. Gonzalez-Lopez
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2016/4193538

Internet

http://dx.doi.org/10.1155/2016/4193538

Similar Items